J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc (NASDAQ:AMRX), noting the company’s generics business is increasingly ...

Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) reported fourth-quarter adjusted EPS of 12 cents, down from 14 cents a year ago and ...

The country’s only manufacturer of generic abortion medication asked to be a part of the first legal fight over the procedure ...

There's little doubt that the FDA rulings shoot big holes in the 180 days of exclusivity that Hatch-Waxman gives to the first generic maker to get marketing permission for a drug going off patent.

The company's focus on generic drugs, biosimilars, and specialty pharmaceuticals has garnered attention from analysts who see potential for sustained expansion. This comprehensive analysis ...

Indian generic injectables maker Gland Pharma reported a 7% rise in third-quarter profit on Monday, as lower expenses helped mitigate the impact from production issues at its French unit Cenexi.

The generic drug was launched in September. J.P. Morgan analyst Chris Schott reports that Crexont prescriptions are nearing 1,000 per week, with 964 recorded in the week of February 14.